PRESS RELEASES

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1 ddPCR Assay Measures mRNA Expressions from Immune and Cancer Cell; Key Step In Development of Immunotherapy Test New data from Biodesix® evaluating an assay in development demonstrated the potential...

Clin-TOF Successfully Integrated into VeriStrat® Workflow

Clin-TOF Successfully Integrated into VeriStrat® Workflow

Study Results, Presented at MSACL, Advance Biodesix®/Bioyong Agreement Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat®...

Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

Biodesix won the award for “Innovative Company of the Year” last night at the 2016 IQ Awards and Innovation Summit presented by BizWest Media. The other finalists in the category were Fort Collins-based Madwire and n.io of Broomfield. “We are really in the business of...

Biodesix’s Diagnostic Cortex™ Platform Used In Three Studies Presented at SITC

“The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision to optimize benefit,” said Dr. Jeffrey Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU-Langone Medical Center in New York City.

Subscribe to the Blog